Yutani Y, Ohashi H, Nishimura N, Yamano Y
Department of Orthopedics, Osaka City University Medical School, Japan.
Osaka City Med J. 1995 Dec;41(2):63-73.
We investigated the status of the development of heterotopic ossification and compared the frequency of heterotopic ossification in the EHDP group with that in the untreated (control) group to evaluate the efficacy and safety of EHDP. Seventy-seven patients who had undergone total hip arthroplasty or femoral head prosthesis for the treatment of osteoarthritis and femoral neck fracture were enrolled in the study. Heterotopic ossification surrounding the hip joint was evaluated according to the roentgenographic classification. In the control group, heterotopic ossification was found in 10 patients (20%) during the period, while in the EHDP group, it was found in one patient (3.7%) during the treatment period after the operation. Gastrointestinal disorder, in one case only was a side effect observed during EHDP treatment. It was revealed that EHDP inhibits heterotopic ossification following total hip replacement in patients with osteoarthritis.
我们研究了异位骨化的发展状况,并比较了依替膦酸二钠(EHDP)组与未治疗(对照)组异位骨化的发生率,以评估EHDP的疗效和安全性。77例因骨关节炎和股骨颈骨折接受全髋关节置换术或股骨头假体植入术的患者纳入本研究。根据X线分类评估髋关节周围的异位骨化情况。对照组在此期间有10例患者(20%)出现异位骨化,而EHDP组在术后治疗期间有1例患者(3.7%)出现异位骨化。EHDP治疗期间仅观察到1例胃肠道紊乱的副作用。结果显示,EHDP可抑制骨关节炎患者全髋关节置换术后的异位骨化。